Reuters -- Amgen's keenly awaited new osteoporosis drug denosumab has been recommended for approval in Europe, the European Medicines Agency said on Friday. GlaxoSmithKline will help commercialise the biotech bone drug in Europe, throwing its marketing weight behind a product that analysts expect to make billions of dollars in annual sales.
